Immunosuppression switch in pediatric heart transplant recipients: Cyclosporine to FK 506

Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506.

OBJECTIVES We studied rejection, allograft function and side effects, such as hypertension, renal dysfunction and hypercholesterolemia, in seven patients switched from cyclosporine-based triple-drug immunosuppression to FK 506. BACKGROUND A subset of pediatric heart transplant recipients treated with triple-drug immunosuppression consisting of cyclosporine, azathioprine and prednisone experie...

Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.

C YCLOSPORINE (CyA) has been a major advance in the armamentarium of immunosuppressive agents used in clinical transplantation. The use of Cy A and steroids has increased patient and graft survival in human transplantation. 1 ,2 Rejection continues to be the most common cause of retransplantation, and death is often a sequela of treatment of rejection. A number of adverse effects of CyA have be...

The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression.

ASPERGILLOSIS is the second most imponant cause of fungal. infection after liver transplantaUon (LTx). with a mortality approaching 100%. In a previous study, we observed a 4% frequency of invasive aspergillosis in 101 consecutive LTx recipients. I Outcome depends on early treatment. however. the diagnosis of this disease is very difficult.2 The introduction of FK 506. allowed us to evaluate th...

FK 506 conversion of renal allografts failing cyclosporine immunosuppression.

FK 506 versus cyclosporine.